Founded in 1994, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma,” stock code: 600196.SH, 02196.HK) is a global, innovation-driven pharmaceutical and healthcare group rooted in China. Its direct businesses include pharmaceuticals, medical devices and diagnostics, and healthcare services, and its equity stake in Sinopharm Group extends into the pharmaceutical commercial sector.

Fosun Pharma is patient-centric and clinically driven, enriching its innovative product pipeline through a diverse and multi-tiered collaboration model encompassing independent R&D, collaborative development, licensing, and deep incubation. Focusing on key disease areas such as oncology and immune regulation, metabolism and digestive system, and the central nervous system, Fosun Pharma has established and developed technology platforms for innovative small molecule drugs, antibody drugs, and cell therapy. The company is also actively exploring cutting-edge technologies such as RNA, oncolytic viruses, gene therapy, and targeted protein degradation to enhance its innovation capabilities.

Under the strategic guidance of “4IN” (Innovation, Internationalization, Integration, Intelligentization), Fosun Pharma will adhere to the development model of “innovative transformation, integrated operations, and steady growth” and the belief in creating value for shareholders. It will continuously strengthen its innovative R&D and licensing capabilities, enrich its product line, and strengthen its global layout. At the same time, it will actively promote the online and offline layout of the medical and health industry, and strive to become a first-class company in the global medical and health market.